AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane) in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.
- 07 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 27 Apr 2018 New trial record